Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

August 2020 – Immunotherapy

Immunotherapy: Innovating the Way We Treat Cancer
Dive into this special issue focused on immunotherapy, the innovative methods of treating cancer today, with this introduction by Lillie Shockney, RN, BS, MAS, HON-ONN-CG. Read More ›

From the Brink of Death to the Top of a Mountain: The Magic of CAR T-Cell Immunotherapy
Laurie Adami chronicles her long fight with follicular lymphoma, including her run-in with 6 types of therapies. After losing all hope, she finally achieved complete remission with a new immunotherapy called CAR T-cell therapy, and then turned her sights on climbing Mt. Everest to raise money for cancer research. Read More ›

What Is Immunotherapy, and How Does It Work Against Cancer?
Not sure what immunotherapy is and how it works? Read about the cellular mechanism and the various types of immunotherapies, including those that use your own immune system to destroy cancer cells. This article also addresses the side effects of immunotherapy. Read More ›

Immunotherapy with Libtayo Prolongs Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
Cutaneous squamous-cell carcinoma (CSCC), or skin cancer, is the second most common cancer in the United States. This article examines the results of a recent study on the first and only immunotherapy approved for patients with advanced or metastatic CSCC. Read More ›

Immunotherapy plus Chemotherapy a New Standard of Care for Patients with Extensive-Stage Small-Cell Lung Cancer
About 15% of lung cancers are small-cell lung cancer, and about one-third of those are extensive-stage small-cell lung cancer. In March 2020, the FDA approved the first immunotherapy, for use with chemotherapy, for first-line treatment of patients with extensive-stage small-cell lung cancer. Read More ›

First-Line Immunotherapy New Standard of Care in Some Patients with Metastatic Colorectal Cancer
A new study was presented at the 2020 ASCO meeting that compared, for the first time, the use of immunotherapy versus chemotherapy for treating patients with metastatic colorectal cancer and microsatellite instability-high or mismatch repair-deficient abnormalities. Read More ›

Keytruda Immunotherapy Prolongs Survival in Patients with Relapsed or Refractory Hodgkin Lymphoma
This article discusses findings from a clinical trial showing that Keytruda prolongs the time without disease progression in patients with relapsed or refractory classical Hodgkin lymphoma compared with the current standard of therapy. Read More ›

Tecentriq plus Avastin First Immunotherapy Combination Approved as First-Line Treatment of Advanced Liver Cancer
In May 2020, the FDA approved the combination of 2 immunotherapies for patients with metastatic hepatocellular carcinoma (liver cancer) who have not received systemic therapy and cannot be treated by surgery. Read More ›

Immunotherapy with Opdivo Approved for Advanced Esophageal Cancer
In June 2020, the FDA approved a new indication for Opdivo, a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma, after the use of chemotherapy. Read More ›